drugset / Trial / NCT05199194
Randomization to Endovascular Treatment Alone or Preceded by Systemic Thrombolysis With Tenecteplase in Ischemic Stroke
Phase 3
Recruiting
398 enrolled
Hospital Moinhos de Vento
Boehringer Ingelheim · collabMedtronic · collabMinistry of Health, Brazil · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A phase III randomized, multi-center, double-blinded, placebo-controlled clinical trial that will examine two strategies for the treatment of acute ischemic stroke associated with a large vessel anterior occlusion within 4.5 hours from symptoms onset: direct endovascular treatment vs. endovascular treatment preceded by intravenous tenecteplase.
Timeline
- Start
- 2022-05-27
- Primary completion
- 2026-07
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenecteplase | Protein / enzyme biologic | 0.25 mg/kg | Intravenous |